💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Bajaj Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in activities of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), bulk drugs, branded and generic formulations. It is focused on…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, stagnant business, priced for perfection.
Bajaj Healthcare is scored on the pharma / healthcare framework. It keeps a thin 2.5% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 3.68× reported profit. Free cash flow is worth about 1.0% of its market value.
Over the last 3 years revenue compounded at -2%/yr and profit at -28%/yr. Book value has grown 13%/yr. Return on equity is a modest 10.4%. In the latest quarter profit grew 3% versus the prior quarter.
At 62× earnings, the stock sits at the 82nd percentile of its own 2.6-year range — the expensive end of where it has historically traded. Today's price already implies ~22%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 50.87 | — | — |
| P/B | 1.88 | 4.1 | better |
| EV/EBITDA | 16.39 | 19.33 | better |
| ROE | 10.45 | — | — |
| ROCE | 10.75 | 14.41 | worse |
| ROA | 2.1 | 1.64 | better |
| Quick Ratio | 1.14 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Negative CAGR — the top line has shrunk over this window. Growth is decelerating — latest year grew slower than the year before.
1 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a -60% swing — check if it's a one-off or structural.
Operating margin has compressed from 12% to 5% — costs or competition are eating into profitability. Interest or tax burden is shrinking — more of the operating profit is reaching the bottom line.
ROE at 4% — modest; the capital isn't working hard. Capital efficiency declining — ROE down 13pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. Profit grew faster than EPS (-39% vs -43%) — share dilution is eroding per-share value. -43% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
1 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Cash conversion at 3.7× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 6% sequentially — momentum is building.
1 of 4 quarters loss-making — quarterly profitability is uneven.
How today's P/E compares to the stock's own historical range. Dashed line = the 2.6y median.
Promoter holding at 58.6% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.